NT$ 8.5
Key Takeaways
Risk factor
Very high price volatility
Data is available to registered users only
Data is available to registered users only
Profitability factor
Greatly overvalued vs peers
Data is available to registered users only
Data is available to registered users only
About
Duogenic Stemcells Corporation is primarily engaged in the biotechnology and healthcare industries, offering a variety of services. Their core offerings include cell therapy and the development of closed-culture cell systems. The company was established on March 22, 2018, and its main corporate office is situated in Taichung, Taiwan.
Company Valuation
From both historical and forecast perspectives, the stock is considerably overpriced compared to similar stocks.
Data is available to registered users only